Global Meningococcal Vaccines Market Report and Forecast 2023-2031

Global Meningococcal Vaccines Market Report and Forecast 2023-2031


Global Meningococcal Vaccines Market Outlook:


The global meningococcal vaccines market value was USD 3.45 billion in 2022, driven by the increasing prevalence of meningococcal disease across the globe. The market size is anticipated to grow at a CAGR of 6.8% during the forecast period of 2023-2031 to achieve a value of USD 6.24 billion by 2031.

Introduction

Meningococcal vaccines are designed to protect against meningococcal disease, which is caused by the bacterium Neisseria meningitidis. Meningococcal disease can lead to meningitis (inflammation of the membranes surrounding the brain and spinal cord) and septicemia (bloodstream infection), both of which can be life-threatening. Meningococcal vaccines stimulate the immune system to produce an immune response against the bacteria, providing protection against the disease.

Key Trends in the Meningococcal Vaccines Market


Some key trends involved in the meningococcal vaccines market are as follows:

Increasing Global Immunization Efforts: There is a growing emphasis on immunization programs worldwide to combat meningococcal disease. Governments and healthcare organizations are promoting routine immunization of infants and adolescents to reduce the incidence of the disease. This trend is driven by the recognition of the public health impact of meningococcal infections and the availability of effective vaccines.
Expansion of Vaccine Coverage: In recent years, there has been an expansion in the number of countries including meningococcal vaccines in their national immunization schedules. This includes both developed and developing countries, with an aim to protect vulnerable populations and prevent outbreaks. The focus is on providing access to vaccines to those at highest risk, such as infants, adolescents, and individuals living in high-risk areas or participating in certain activities (e.g., travel, military service).
Advancements in Vaccine Technology: The development of new meningococcal vaccines and advancements in vaccine technology are driving the market. These include the introduction of conjugate vaccines, which offer broader protection against multiple serogroups of Neisseria meningitidis. Conjugate vaccines have demonstrated enhanced immunogenicity and longer-lasting protection compared to earlier generations of vaccines. Additionally, efforts are underway to develop vaccines that provide protection against emerging serogroups and to improve the efficacy and duration of immune response.
Focus on Serogroup B Vaccines: Serogroup B of Neisseria meningitidis has historically posed a challenge for vaccine development due to its complex polysaccharide structure. However, there have been significant advancements in the development of serogroup B vaccines, including the use of novel approaches such as recombinant protein-based vaccines and outer membrane vesicle vaccines. This has opened up new possibilities for providing protection against this particular serogroup.

Meningococcal Vaccines Market Segmentations


Market Breakup by Type

Mono Vaccines
Combination Vaccines
Market Breakup by Age Group

Infants
Childrens
Adults
Market Breakup by Brand

Menactra
Menveo
Nimenrix
Trumenba
Bexsero
Others
Market Breakup by End User

Hospitals
Homecare
Specialty Clinics
Others
Market Breakup by Distribution Channel

Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
Others
Market Breakup by Region

North America
United States of America
Canada
Europe
United Kingdom
Germany
France
Italy
Others
Asia Pacific
China
Japan
India
ASEAN
Australia
Others
Latin America
Brazil
Argentina
Mexico
Others
Middle East and Africa
Saudi Arabia
United Arab Emirates
Nigeria
South Africa
Others

Meningococcal Vaccines Market Scenario


The global market for meningococcal vaccines is experiencing significant growth due to the increasing incidence of meningococcal disease and the growing awareness about the importance of vaccination. Meningococcal disease is a serious public health concern, and the demand for effective vaccines is driving the market growth.

Several factors contribute to the market expansion. First, governments and healthcare organizations are implementing robust immunization programs to prevent meningococcal infections. This includes the incorporation of meningococcal vaccines into national immunization schedules and the promotion of routine vaccination for at-risk populations. This focus on immunization is creating a favourable market environment for meningococcal vaccines.

Geographically, the market for meningococcal vaccines is witnessing growth across regions. Developed countries have well-established immunization programs, while developing countries are expanding their vaccination efforts to combat the disease burden. Additionally, travel-related vaccinations and initiatives aimed at preventing outbreaks in high-risk areas contribute to the market growth.

Meningococcal Vaccines Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

Johnson & Johnson Private Limited
Mylan N.V.
Sun Pharmaceutical Industries Limited
Sanofi S.A.
Merck & Co., Inc.
GSK plc.
Novartis AG
AbbVie Inc.
Fresenius Kabi AG
Amneal Pharmaceuticals LLC.
Pfizer Inc.
Serum Institute of India Pvt. Ltd.
Incepta Pharmaceuticals Ltd.
Walvax Biotechnology Co., Ltd.
Bio-Manguinhos


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Meningococcal Vaccines Market Overview
3.1 Global Meningococcal Vaccines Market Historical Value (2016-2022)
3.2 Global Meningococcal Vaccines Market Forecast Value (2023-2031)
4 Global Meningococcal Vaccines Market Landscape
4.1 Global Meningococcal Vaccines Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Meningococcal Vaccines Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by End User
4.2.3 Analysis by Major Regions
5 Global Meningococcal Vaccines Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Meningococcal Vaccines Market Segmentation
6.1 Global Meningococcal Vaccines Market by Type
6.1.1 Market Overview
6.1.2 Mono Vaccines
6.1.3 Combination Vaccines
6.2 Global Meningococcal Vaccines Market by Age Group
6.2.1 Market Overview
6.2.2 Infants
6.2.3 Childrens
6.2.4 Adults
6.3 Global Meningococcal Vaccines Market by Brand
6.3.1 Market Overview
6.3.2 Menactra
6.3.3 Menveo
6.3.4 Nimenrix
6.3.5 Trumenba
6.3.6 Bexsero
6.3.7 Others
6.4 Global Meningococcal Vaccines Market by End User
6.4.1 Market Overview
6.4.2 Hospitals
6.4.3 Homecare
6.4.4 Specialty Clinics
6.4.5 Others
6.5 Global Meningococcal Vaccines Market by Distribution Channel
6.5.1 Market Overview
6.5.2 Hospital Pharmacy
6.5.3 Online Pharmacy
6.5.4 Retail Pharmacy
6.5.5 Others
6.6 Global Meningococcal Vaccines Market by Region
6.6.1 Market Overview
6.6.2 North America
6.6.3 Europe
6.6.4 Asia Pacific
6.6.5 Latin America
6.6.6 Middle East and Africa
7 North America Meningococcal Vaccines Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Meningococcal Vaccines Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Meningococcal Vaccines Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Meningococcal Vaccines Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Meningococcal Vaccines Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 Johnson & Johnson Private Limited
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Mylan N.V.
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Sun Pharmaceutical Industries Limited
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Sanofi S.A.
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Merck & Co., Inc.
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 GSK plc.
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Novartis AG
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 AbbVie Inc.
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Fresenius Kabi AG
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Amneal Pharmaceuticals LLC.
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Pfizer Inc.
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Serum Institute of India Pvt. Ltd.
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 Incepta Pharmaceuticals Ltd.
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
17.14 Walvax Biotechnology Co., Ltd.
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
17.14.5 Certifications
17.15 Bio-Manguinhos
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisitions
17.15.5 Certifications
18 Global Meningococcal Vaccines Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings